Clinical Trial Update: A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase II study of TPI 287 in patients with advanced, unresectable pancreatic cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• TPI-287

Snippet

Sponsor: Cortice Biosciences, Inc. | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED